Please find enclosed the Notice of Postal Ballot together with Explanatory Statement benig sent to the members of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma Industries is seeking shareholder approval via postal ballot for: (1) Migrating 24.06 crore equity shares from BSE SME Platform to BSE Main Board and simultaneously applying for NSE Main Board listing; (2) Appointing Mr. Sanat Bhat as Independent Director for 5 years (May 2026-April 2031), a Chartered Accountant with 13+ years in Transaction Advisory and Investment Banking; (3) Appointing Dr. Vinay Pandey as Non-Executive Non-Independent Director. The company listed on BSE SME in March 2023 after raising Rs 5,009.55 lakh via IPO, and now meets eligibility criteria (listed >3 years, paid-up capital >Rs 10 crore) for Main Board migration. Voting period: May 26 to June 24, 2026. Note: Company is currently under Enhanced Surveillance Measure (ESM) framework and will file migration application upon exit from ESM.
Migration to Main Board of BSE and NSE listing would increase visibility, attract broader retail participation, and potentially enhance liquidity and valuation. The new director appointments strengthen the board with finance and governance expertise. However, the ESM classification may delay the migration process.